Hans Basun

TL;DR: A multidisciplinary, international group of experts discussed the current status and future directions of MCI, with regard to clinical presentation, cognitive and functional assessment, and the role of neuroimaging, biomarkers and genetics.

TL;DR: Administration of omega-3 fatty acid in patients with mild to moderate AD did not delay the rate of cognitive decline according to the MMSE or the cognitive portion of the Alzheimer Disease Assessment Scale, and positive effects were observed in a small group of patients with very mild AD.

TL;DR: This study suggests that vitamin B12 and folate may be involved in the development of AD, as a clear association was detected only when both vitamins were taken into account, especially among the cognitively intact subjects.

TL;DR: The notion that lithium treatment may lead to reduced hyperphosphorylation of tau protein after a short 10-week treatment in the Alzheimer's disease target population is not supported.

TL;DR: It is concluded that T-tau, P-t Tau and Abeta42 concentrations in CSF are remarkably stable over a 6-month period in individual AD patients, suggesting that these biomarkers may have a potential to identify and monitor very minor biochemical changes induced by treatment, and thus support their possible usefulness in clinical trials with drug candidates with disease-modifying potential.